Official Gene Symbol | Other Aliases |
---|---|
KRT7 | SCL |
Sequence Length (AA) | Molecular Weight (Da) |
---|---|
469 | 51386 |
Protein Name |
---|
Keratin, type II cytoskeletal 7 |
Sources | |
---|---|
UniProt PhosphoSitePlus ® GeneCards |
Human Protein Atlas |
10 | 20 | 30 | 40 | 50 |
MSIHFSSPVF | TSRSAAFSGR | GAQVRLSSAR | PGGLGSSSLY | GLGASRPRVA |
60 | 70 | 80 | 90 | 100 |
VRSAYGGPVG | AGIREVTINQ | SLLAPLRLDA | DPSLQRVRQE | ESEQIKTLNN |
110 | 120 | 130 | 140 | 150 |
KFASFIDKVR | FLEQQNKLLE | TKWTLLQEQK | SAKSSRLPDI | FEAQIAGLRG |
160 | 170 | 180 | 190 | 200 |
QLEALQVDGG | RLEAELRSMQ | DVVEDFKNKY | EDEINHRTAA | ENEFVVLKKD |
210 | 220 | 230 | 240 | 250 |
VDAAYMSKVE | LEAKVDALND | EINFLRTLNE | TELTELQSQI | SDTSVVLSMD |
260 | 270 | 280 | 290 | 300 |
NSRSLDLDGI | IAEVKAQYEE | MAKCSRAEAE | AWYQTKFETL | QAQAGKHGDD |
310 | 320 | 330 | 340 | 350 |
LRNTRNEISE | MNRAIQRLQA | EIDNIKNQRA | KLEAAIAEAE | ERGELALKDA |
360 | 370 | 380 | 390 | 400 |
RAKQEELEAA | LQRGKQDMAR | QLREYQELMS | VKLALDIEIA | TYRKLLEGEE |
410 | 420 | 430 | 440 | 450 |
SRLAGDGVGA | VNISVMNSTG | GSSSGGGIGL | TLGGTMGSNA | LSFSSSAGPG |
460 | 469 | |||
LLKAYSIRTA | SASRRSARD |
Data source: UniProt
Uniprot Database Entry PhosphoSitePlus ®
loading
Data source: Panorama
View Details (opens in a new window)
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Clin Chem. 2021 Jun 17:hvab047. doi: 10.1093/clinchem/hvab047. Online ahead of print. PMID: 34136904
Data source: Panorama
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y11 (1+) | 20 | 34.4 | 19.7 | 36.7 | 68.3 | 70 | 41.8 | 76.5 | 72.7 | 15 | 17 | 15 |
y9 (1+) | 17.4 | 29.1 | 20.2 | 35.2 | 65.2 | 67.5 | 39.3 | 71.4 | 70.5 | 15 | 17 | 15 |
y8 (1+) | 17.2 | 30.1 | 17.8 | 33.9 | 66.5 | 66.6 | 38 | 73 | 68.9 | 15 | 17 | 15 |
y7 (1+) | 13.6 | 31.6 | 21.1 | 34 | 68.1 | 70.4 | 36.6 | 75.1 | 73.5 | 15 | 17 | 15 |
y12 (2+) | 17 | 30.2 | 20 | 38.3 | 64.8 | 70.3 | 41.9 | 71.5 | 73.1 | 15 | 17 | 15 |
sum | 16.2 | 30.1 | 19.6 | 35.2 | 66.1 | 68.6 | 38.7 | 72.6 | 71.3 | 15 | 17 | 15 |
Data source: Panorama
View Details (opens in a new window)
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Clin Chem. 2021 Jun 17:hvab047. doi: 10.1093/clinchem/hvab047. Online ahead of print. PMID: 34136904
Data source: Panorama
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y7 (1+) | 12.3 | 7.2 | 25.3 | 10 | 10.7 | 27.3 | 15.9 | 12.9 | 37.2 | 12 | 12 | 12 |
y8 (1+) | 11.7 | 8.9 | 21.6 | 8.6 | 10.6 | 23.1 | 14.5 | 13.8 | 31.6 | 12 | 12 | 12 |
y9 (1+) | 11.3 | 8.8 | 19.9 | 11 | 13.4 | 23.1 | 15.8 | 16 | 30.5 | 12 | 12 | 12 |
y11 (1+) | 15.7 | 11.3 | 21.6 | 15.8 | 14.7 | 26.4 | 22.3 | 18.5 | 34.1 | 12 | 12 | 12 |
y12 (2+) | 8.2 | 6.3 | 16.8 | 6.5 | 14.2 | 20.8 | 10.5 | 15.5 | 26.7 | 12 | 12 | 12 |
sum | 9.8 | 7.7 | 20.5 | 8.8 | 11.9 | 23.3 | 13.2 | 14.2 | 31 | 12 | 12 | 12 |
Data source: Panorama
View Details (opens in a new window)
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Clin Chem. 2021 Jun 17:hvab047. doi: 10.1093/clinchem/hvab047. Online ahead of print. PMID: 34136904
Data source: Panorama
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y8 (1+) | 12.9 | 3.4 | 4.5 | 12 | 6 | 4.9 | 17.6 | 6.9 | 6.7 | 15 | 17 | 15 |
y10 (1+) | 13.1 | 3.9 | 2.3 | 10.1 | 4.8 | 2.7 | 16.5 | 6.2 | 3.5 | 15 | 17 | 15 |
y9 (1+) | 12.4 | 3.6 | 3.9 | 10.4 | 6 | 4.4 | 16.2 | 7 | 5.9 | 15 | 17 | 15 |
y7 (1+) | 12.5 | 3.5 | 3.7 | 11 | 5.5 | 3.4 | 16.7 | 6.5 | 5 | 15 | 17 | 15 |
y10 (2+) | 11.1 | 2.2 | 3 | 11 | 4.4 | 3.5 | 15.6 | 4.9 | 4.6 | 15 | 17 | 15 |
sum | 11.5 | 1.7 | 2.3 | 10 | 4.6 | 2.3 | 15.2 | 4.9 | 3.3 | 15 | 17 | 15 |
Data source: Panorama
View Details (opens in a new window)
Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Clin Chem. 2021 Jun 17:hvab047. doi: 10.1093/clinchem/hvab047. Online ahead of print. PMID: 34136904
Data source: Panorama
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y10 (2+) | 10.9 | 3.1 | 4.9 | 11.2 | 4.1 | 5.7 | 15.6 | 5.1 | 7.5 | 12 | 12 | 12 |
y7 (1+) | 12.9 | 3.6 | 4.3 | 13.5 | 3.6 | 3.3 | 18.7 | 5.1 | 5.4 | 12 | 12 | 12 |
y8 (1+) | 11.4 | 4.9 | 2.6 | 13.2 | 6.3 | 2.4 | 17.4 | 8 | 3.5 | 12 | 12 | 12 |
y9 (1+) | 14.2 | 4.8 | 2.2 | 14.3 | 4.7 | 2.4 | 20.2 | 6.7 | 3.3 | 12 | 12 | 12 |
y10 (1+) | 14.5 | 6.5 | 2.1 | 14.6 | 6.4 | 2.5 | 20.6 | 9.1 | 3.3 | 12 | 12 | 12 |
sum | 11.9 | 2.9 | 2.4 | 12.2 | 3.3 | 2.6 | 17 | 4.4 | 3.5 | 12 | 12 | 12 |
Data source: Panorama
Data source: Panorama
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y10 (2+) | 5.8 | 8 | 3 | 40.3 | 29.3 | 29.2 | 40.7 | 30.4 | 29.4 | 15 | 15 | 15 |
y7 (1+) | 6.1 | 7.7 | 2.2 | 25.7 | 27.7 | 28.3 | 26.4 | 28.8 | 28.4 | 15 | 15 | 15 |
y9 (1+) | 4.7 | 5.4 | 0.9 | 38 | 29.1 | 29.6 | 38.3 | 29.6 | 29.6 | 15 | 15 | 15 |
sum | 3 | 6.6 | 1.4 | 35.4 | 28.8 | 29.1 | 35.5 | 29.5 | 29.1 | 15 | 15 | 15 |
Data source: Panorama
Data source: Panorama
Data source: Panorama
Data source: Panorama
Retrieving Data
Data source: Panorama
Average intra-assay CV (within day CV) |
Average inter-assay CV (between day CV) |
Total CV |
n= | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
y7 (1+) | 8.6 | 5.9 | 1.6 | 51 | 39.2 | 43.1 | 51.7 | 39.6 | 43.1 | 15 | 15 | 15 |
y8 (1+) | 5.6 | 5.2 | 2.8 | 47.9 | 40.9 | 44.6 | 48.2 | 41.2 | 44.7 | 15 | 15 | 15 |
y10 (1+) | 4.6 | 5.3 | 3.1 | 52.2 | 41.5 | 44.6 | 52.4 | 41.8 | 44.7 | 15 | 15 | 15 |
sum | 3.7 | 5.1 | 2 | 50.2 | 40.7 | 44.2 | 50.3 | 41 | 44.2 | 15 | 15 | 15 |
Comments